Literature DB >> 16379648

Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.

Dianne McFarlane1, Alastair E Cribb.   

Abstract

OBJECTIVE: To determine whether a deficiency in systemic or local (pars intermedia) antioxidant capacity is associated with pituitary pars intermedia oxidative stress and pituitary pars intermedia dysfunction (PPID) in horses. SAMPLE POPULATION: Blood samples from 20 horses with PPID and 20 healthy client-owned horses, archived paraffin-embedded adrenal gland and substantia nigra tissues from 20 horses, and pituitary gland tissue from 16 horses. PROCEDURES: Total glutathione, superoxide dismutase, and glutathione peroxidase activities were determined in RBCs. Accumulation of a systemic marker of oxidative stress (3-nitrotyrosine) was assessed in plasma and formalin-fixed, paraffin-embedded adrenal gland and substantia nigra tissues. Local antioxidants (total and manganese superoxide dismutase, glutathione peroxidase, and total glutathione) were measured in pars intermedia tissues.
RESULTS: No significant differences existed in systemic antioxidant enzyme activity or accumulation of 3-nitrotyrosine between horses with PPID and control horses. In pituitary gland tissues, glutathione peroxidase activity was increased in horses with oxidative stress, whereas total glutathione concentration and superoxide dismutase activity remained unchanged. There was an age-associated decrease in manganese superoxide dismutase activity in the pars intermedia. CONCLUSIONS AND CLINICAL RELEVANCE: There was no evidence of systemic accumulation of oxidative stress markers or deficiencies in antioxidant capacity in horses with PPID, suggesting that these are unlikely to be major predisposing factors in the development of PPID. Manganese superoxide dismutase activity in the pars intermedia decreased significantly with increasing age. Role of an age-associated decrease in antioxidant capacity for the pars intermedia in the development of PPID in horses warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379648     DOI: 10.2460/ajvr.2005.66.2065

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Relationship of oxidative stress in skeletal muscle with obesity and obesity-associated hyperinsulinemia in horses.

Authors:  Heidi E Banse; Nicholas Frank; Grace P S Kwong; Dianne McFarlane
Journal:  Can J Vet Res       Date:  2015-10       Impact factor: 1.310

2.  Effects of Advanced Age, Pituitary Pars Intermedia Dysfunction and Insulin Dysregulation on Serum Antioxidant Markers in Horses.

Authors:  Agnieszka Żak; Natalia Siwińska; Elżbieta Chełmecka; Barbara Bażanów; Ewa Romuk; Amanda Adams; Artur Niedźwiedź; Dominika Stygar
Journal:  Antioxidants (Basel)       Date:  2020-05-21

3.  Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Authors:  Rebecca C Tatum; Cathy M McGowan; Rachel S Dean; Joanne L Ireland
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

4.  Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.

Authors:  Jessica S Fortin; Ashley A Hetak; Kelsey E Duggan; Caroline M Burglass; Hailey B Penticoff; Harold C Schott
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

Review 5.  Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.

Authors:  Caroline W Spelta
Journal:  Vet Med (Auckl)       Date:  2015-08-20

6.  Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.

Authors:  Jessica S Fortin; Matthew J Benskey; Keith J Lookingland; Jon S Patterson; Erin B Howey; John L Goudreau; Harold C Schott
Journal:  BMC Vet Res       Date:  2020-09-25       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.